GSK invests in UK biotech start-up
GSK announced that it has taken a ~25% stake in a new spin out. This is a terrific way to create new companies and advance more molecules into the clinic,…
Menu
Summer Blogging
Posts have been light lately, due to vacations, summer hours, etc. However, we've remained busy with client work and keeping up with the news. A few recent news items of…
Biosimilars: Are We There Yet?
Today's New England Journal of Medicine contains a short article by Kozlowski et al entitled Developing the Nation's Biosimilars Program (link to PDF). Here, the authors attempt t provide a…
All you need is…guts
Luke Timmerman at Xconomy wrote a provocative piece today entitled The Missing Ingredient in Today's Biotech: Guts. His thesis is that the industry is so paralyzed by fear and insecurity that it lacks…
BIO Convention and Business Socialization
We previously posted our comments on BIO 2011. However, one aspect of the conference that really stood out was the use of social media. Attendees were encouraged to provide links…
Observations from BIO 2011
The Lacerta Bio team attended the annual BIO Convention in Washington, DC last week. BIO has become one of the key conventions for pharma/biotech business development, and is a "must…
Is deal-making becoming more difficult?
The June, 2011 issue of Nature Drug Discovery has a interesting short article based on a survey conducted by our good friends at PharmaVentures. The authors surveyed 180 business development…
The SmartCells Story
Bruce Booth from Atlas Ventures has a fascinating story on his blog. We won't steal Bruce's thunder. Instead, we encourage you to read it there first. The gist of the story is…
The Era of the One Man Pharma Band (With Updates)
There is a fascinating discussion taking place over at Derek Lowe's blog today on one-man drug companies: ...some of them are not quite down to one person, but you can…